Tags

Type your tag names separated by a space and hit enter

Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients.
Diabetes Res. 1987 Nov; 6(3):155-8.DR

Abstract

Continuous subcutaneous insulin infusion (CSII) of 6 months duration was compared with 6 months of multiple insulin injections (MII) using a pen injector (NovoPen) in a prospective cross-over study with 20 young insulin dependent diabetics by evaluating metabolic control, insulin requirements and patient acceptability. Following both intensified regimens (CSII/MII) serum fructosamine declined significantly from 4.1 +/- 0.7 to 3.4 +/- 0.5 mmol/l and 3.6 +/- 0.7 mmol/l respectively (normal range: 2.2 +/- 0.2 mmol/l). When comparing CSII and MII no significant differences could be demonstrated in mean blood glucose (MBG), fasting plasma ketone bodies, fasting plasma free fatty acids (FFA), fasting plasma human growth hormone (HGH), fasting plasma glucagon or serum fructosamine. Mean insulin requirement was 11.4% higher during MII and glucose instability--demonstrated by the M-values and by the frequency of blood glucose values below 4 mmol/l--was significantly (p less than 0.02) higher during the MII treatment. All of the patients reported a better well-being on both treatment regimens and none of them wanted to go back to conventional therapy (CT). In conclusion, on a long-term basis both regimens result in identical metabolic control, but due to physical discomfort during pump treatment, the insulin pen injector was preferred by the majority (80%) of the patients.

Authors+Show Affiliations

Bak JF
Department of Endocrinology and Internal Medicine, Aarhus County Hospital, Tage Hansensgade, Denmark.
Nielsen OH
No affiliation info available
Pedersen O
No affiliation info available
Beck-Nielsen H
No affiliation info available

MeSH

AdultClinical Trials as TopicDiabetes Mellitus, Type 1Drug Administration ScheduleFemaleHumansInjections, SubcutaneousInsulinInsulin Infusion SystemsMaleProspective Studies

Pub Type(s)

Clinical Trial
Comparative Study
Controlled Clinical Trial
Journal Article
Research Support, Non-U.S. Gov't

Language

eng

PubMed ID

3325220

Citation

Bak, J F., et al. "Multiple Insulin Injections Using a Pen Injector Versus Insulin Pump Treatment in Young Diabetic Patients." Diabetes Research (Edinburgh, Scotland), vol. 6, no. 3, 1987, pp. 155-8.
Bak JF, Nielsen OH, Pedersen O, et al. Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Res. 1987;6(3):155-8.
Bak, J. F., Nielsen, O. H., Pedersen, O., & Beck-Nielsen, H. (1987). Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. Diabetes Research (Edinburgh, Scotland), 6(3), 155-8.
Bak JF, et al. Multiple Insulin Injections Using a Pen Injector Versus Insulin Pump Treatment in Young Diabetic Patients. Diabetes Res. 1987;6(3):155-8. PubMed PMID: 3325220.
* Article titles in AMA citation format should be in sentence-case
TY - JOUR T1 - Multiple insulin injections using a pen injector versus insulin pump treatment in young diabetic patients. AU - Bak,J F, AU - Nielsen,O H, AU - Pedersen,O, AU - Beck-Nielsen,H, PY - 1987/11/1/pubmed PY - 1987/11/1/medline PY - 1987/11/1/entrez SP - 155 EP - 8 JF - Diabetes research (Edinburgh, Scotland) JO - Diabetes Res VL - 6 IS - 3 N2 - Continuous subcutaneous insulin infusion (CSII) of 6 months duration was compared with 6 months of multiple insulin injections (MII) using a pen injector (NovoPen) in a prospective cross-over study with 20 young insulin dependent diabetics by evaluating metabolic control, insulin requirements and patient acceptability. Following both intensified regimens (CSII/MII) serum fructosamine declined significantly from 4.1 +/- 0.7 to 3.4 +/- 0.5 mmol/l and 3.6 +/- 0.7 mmol/l respectively (normal range: 2.2 +/- 0.2 mmol/l). When comparing CSII and MII no significant differences could be demonstrated in mean blood glucose (MBG), fasting plasma ketone bodies, fasting plasma free fatty acids (FFA), fasting plasma human growth hormone (HGH), fasting plasma glucagon or serum fructosamine. Mean insulin requirement was 11.4% higher during MII and glucose instability--demonstrated by the M-values and by the frequency of blood glucose values below 4 mmol/l--was significantly (p less than 0.02) higher during the MII treatment. All of the patients reported a better well-being on both treatment regimens and none of them wanted to go back to conventional therapy (CT). In conclusion, on a long-term basis both regimens result in identical metabolic control, but due to physical discomfort during pump treatment, the insulin pen injector was preferred by the majority (80%) of the patients. SN - 0265-5985 UR - https://www.unboundmedicine.com/medline/citation/3325220/Multiple_insulin_injections_using_a_pen_injector_versus_insulin_pump_treatment_in_young_diabetic_patients_ DB - PRIME DP - Unbound Medicine ER -